HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece

Rigopoulou, Eirini I.; Stefanidis, Ioannis; Liaskos, Christos; Zervou, Eleftheria; Rizos, C.; Mina, Paraskevi; Zachou, Kalliopi; Syrganis, Christos; Patsidis, Eftichios; Kyriakopoulos, George; Sdrakas, Lambros; Tsianas, Nikolaos; Dalekos, Georgios N.

doi:10.1016/j.jcv.2005.05.007

Cited by 48 publications

(36 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a few studies with a small number of patients have been published. Two surveys reported on the presence of anti-HCV-negative patients on regular dialysis with detectable HCV RNA in serum by TMA technique; their frequency ranging between 7.8% and 15.8% by second 23 or third 22 generation ELISA testing. The authors suggested that HCV RNA qualitative assay based on TMA technique improves the accuracy for detecting HCV infection in this population.…”

Section: Discussionmentioning

confidence: 99%

“…The authors suggested that HCV RNA qualitative assay based on TMA technique improves the accuracy for detecting HCV infection in this population. 22,23 Only one study exists on the comparison between TMA and PCR techniques in assessing HCV viremia in dialysis population 21 ; Khan and coworkers found three patients being positive by TMA but not by PCR in their subset of EIA-negative patients. 21 An improved sensitivity by TMA over PCR technology was suggested.…”

Section: Discussionmentioning

confidence: 99%

“…[17][18][19][20] A new HCV RNA qualitative assay (Versant™ HCV RNA Qualitative Assay), which is based on transcriptionmediated amplification (TMA) technology, appears to be very sensitive for detecting HCV RNA in human plasma and serum specimens but data on its use in the HD population is extremely limited. [21][22][23] The Versant™ HCV RNA Qualitative Assay is an in vitro diagnostic device that employs technology equivalent to GenProbe's other currently marketed amplified nucleic acid assays including the Procleix™ HIV-1/HCV Assay 24 and the Aptima™ Combo 2 Assay. 25 In effect, the Procleix™ HIV-1/HCV Assay is identical to the Versant HCV TMA Assay except for the intended usethe Versant™ HCV RNA Qualitative Assay is indicated for use in serum or plasma from patients suspected to be infected with replicative HCV infection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population

et al. 2010

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) infection remains common among patients undergoing maintenance dialysis and plays an adverse effect on survival in this population. Accurate detection of HCV viremia (HCV RNA) in dialysis patients requires a sensitive and specific diagnostic test. Methods: The Versant™ HCV RNA Qualitative Assay, based on transcription-mediated amplification (TMA) technique, was prospectively evaluated in 112 dialysis patients. Performance characteristics of the Versant HCV TMA Assay were evaluated in comparison to the Amplicor ® 2.0 HCV test based on polymerase chain reaction (PCR) technique. In addition, anti-HCV serologic tests including third-generation enzyme immunoassay and Recombinant Immunoblot Assay were performed. Results: Of the 112 specimens tested, 29 were reactive by Versant HCV TMA Assay, yielding an overall prevalence of HCV viremia of 25.9%. The concordance between TMA and PCR techniques was excellent [91% (101/112)]. Eleven specimens (10%) were invalid or equivocal by PCR due to interference phenomena; all 11 specimens had valid TMA results (2 patients being TMA reactive and 9 nonreactive). Four specimens [3.6% (4/112)] that tested PCR-negative and HCV TMA nonreactive were anti-HCV seropositive, consistent with resolved HCV infection. In the group of seronegative samples, one was reactive by TMA Assay [1.25% (1/80)]. Conclusions: The HCV TMA technology seems a highly sensitive tool for detecting HCV RNA in the dialysis population, with no evidence of specimen interference. One EIA-negative but HCV-RNA-positive patient by Versant HCV TMA Assay was identified. Prospective clinical trials are under way to assess the clinical impact related to the use of HCV TMA technology in dialysis population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Mello Lde et al [23] , 2007 Lopes et al [24] , 2006 Albuquerque et al [25] , 2005 Carneiro et al [26] , 2001 China Maintain 7.01%-37.34% Ren et al [27] , 2011 Qi et al [28] , 2003 Greece 10%-29% Garinis et al [29] , 1999 Rigopoulou et al [30] , 2005 Sypsa et al [31] , 2005 Sweden 11.0% Almroth et al [32] , 2002 Iran 13.2% Alavian et al [33] , 2003 France 16.3% Salama et al [34] , 2000 Tunisia 19%-41.7% Bouzgarrou et al [35] , 2005 Ayed et al [36] , 2003 Libya 20.5% Daw et al [37] , 2002…”

Section: Risk Factorsmentioning

confidence: 99%

Management of hepatitis C virus infection in hemodialysis patients

Wang

et al. 2014

WJH

View full text Add to dashboard Cite

currently the main treatment strategies for MHD patients with active HCV replication, but how to increase the sustained virological response and decrease the side effects is the key problem. IFNα-free treatments with two or three direct-acting antivirals without ribavirin in MHD patients are waiting for future investigations. Key words: Hemodialysis; Hepatitis C virus; Epidemiology; Risk factors; Prophylaxis; Treatment Core tip: The new hepatitis C virus (HCV) infections during maintenance hemodialysis (MHD) in recent years are mainly caused by the lack of stringent universal precautions. Strict implementation of universal precautions for HCV transmission has led to markedly decreased HCV infections in many hemodialysis units, but the anti-HCV negative HCV infection and occult HCV infection in MHD patients still should be noted. How to increase the sustained virological response and decrease the side effects is the key problem for the currently recommended interferon alpha-based antiviral therapy in MHD patients. Interferon alpha-free treatments with two or three direct-acting antivirals without ribavirin in MHD patients are waiting for future investigations.

show abstract

“…Στον εργαστηριακό έλεγχο, τα επίπεδα της ALT παραµένουν αυξηµένα και το HCV-RNA παραµένει θετικό (Εικόνα 24) (Rigopoulou 2005Β). Εκτός των διακυµάνσεων της ALT χαρακτηριστική είναι συνήθως η παρουσία αυξηµένων επιπέδων γ-GT (υψηλότερα από οποιαδήποτε άλλη µορφή χρόνιας ιογενούς ηπατίτιδας).…”

Section: 23εργαστηριακά-ιστολογικά ευρήµαταunclassified

Δείκτες Οξειδωτικού Στρες Λιπιδίων, DNA Και Πρωτεϊνών Σε Χρόνιες Παθήσεις Του Ήπατος

Kaffe¹,

Καφφέ²

View full text Add to dashboard Cite

show abstract

HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: Results from five hemodialysis units in central Greece

Cited by 48 publications

References 27 publications

Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population

Improved detection of hepatitis C virus infection by transcription-mediated amplification technology in dialysis population

Management of hepatitis C virus infection in hemodialysis patients

Δείκτες Οξειδωτικού Στρες Λιπιδίων, DNA Και Πρωτεϊνών Σε Χρόνιες Παθήσεις Του Ήπατος

Contact Info

Product

Resources

About